These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 17261116)
41. Health status and costs of ambulatory patients with multiple sclerosis in Hungary. Péntek M; Gulácsi L; Rózsa C; Simó M; Iljicsov A; Komoly S; Brodszky V Ideggyogy Sz; 2012 Sep; 65(9-10):316-24. PubMed ID: 23126217 [TBL] [Abstract][Full Text] [Related]
42. Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Krause I; Kern S; Horntrich A; Ziemssen T Mult Scler; 2013 Nov; 19(13):1792-9. PubMed ID: 23635910 [TBL] [Abstract][Full Text] [Related]
43. What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis. Goodwin E; Green C; Hawton A Value Health; 2020 Feb; 23(2):242-250. PubMed ID: 32113630 [TBL] [Abstract][Full Text] [Related]
44. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Versteegh M Pharmacoeconomics; 2016 Nov; 34(11):1133-1144. PubMed ID: 27282692 [TBL] [Abstract][Full Text] [Related]
45. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data]. Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984 [TBL] [Abstract][Full Text] [Related]
46. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599 [TBL] [Abstract][Full Text] [Related]
47. Burden of a multiple sclerosis relapse: the patient's perspective. Oleen-Burkey M; Castelli-Haley J; Lage MJ; Johnson KP Patient; 2012; 5(1):57-69. PubMed ID: 22217263 [TBL] [Abstract][Full Text] [Related]
48. Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure: Multiple Sclerosis Impact Scale-Eight Dimensions-Patient Version (MSIS-8D-P). Goodwin E; Green C; Hawton A Value Health; 2018 Nov; 21(11):1338-1345. PubMed ID: 30442282 [TBL] [Abstract][Full Text] [Related]
49. A health profile of adults with multiple sclerosis living in the community. Vazirinejad R; Lilley J; Ward C Mult Scler; 2008 Sep; 14(8):1099-105. PubMed ID: 18653738 [TBL] [Abstract][Full Text] [Related]
50. Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis. Ghajarzadeh M; Jalilian R; Eskandari G; Ali Sahraian M; Reza Azimi A Disabil Rehabil; 2013 Aug; 35(18):1509-12. PubMed ID: 23237227 [TBL] [Abstract][Full Text] [Related]
51. Physical activity behavior of people with multiple sclerosis: understanding how they can become more physically active. Beckerman H; de Groot V; Scholten MA; Kempen JC; Lankhorst GJ Phys Ther; 2010 Jul; 90(7):1001-13. PubMed ID: 20508028 [TBL] [Abstract][Full Text] [Related]
52. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis. Jelinek GA; Marck CH; Weiland TJ; Pereira N; van der Meer DM; Hadgkiss EJ BMC Neurol; 2015 Aug; 15():132. PubMed ID: 26243188 [TBL] [Abstract][Full Text] [Related]
53. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375 [TBL] [Abstract][Full Text] [Related]
54. New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany. Flachenecker P; Kobelt G; Berg J; Capsa D; Gannedahl M; Mult Scler; 2017 Aug; 23(2_suppl):78-90. PubMed ID: 28643593 [TBL] [Abstract][Full Text] [Related]
55. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy. Ozakbas S; Akdede BB; Kösehasanogullari G; Aksan O; Idiman E J Neurol Sci; 2007 May; 256(1-2):30-4. PubMed ID: 17379247 [TBL] [Abstract][Full Text] [Related]
56. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome. Hirst CL; Ingram G; Pickersgill TP; Robertson NP Mult Scler; 2012 Aug; 18(8):1152-8. PubMed ID: 22217582 [TBL] [Abstract][Full Text] [Related]
57. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. Romberg A; Virtanen A; Ruutiainen J J Neurol; 2005 Jul; 252(7):839-45. PubMed ID: 15765197 [TBL] [Abstract][Full Text] [Related]
59. Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis. Cano SJ; Barrett LE; Zajicek JP; Hobart JC Mult Scler; 2011 Feb; 17(2):214-22. PubMed ID: 20947530 [TBL] [Abstract][Full Text] [Related]
60. Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand. Siritho S; Thavorncharoensap M; Chanatittarat C; Pasogpakdee P; Apiwattanakul M; Prayoonwiwat N; Chankrachang S; Riewpaiboon A; Chaikledkaew U Mult Scler Relat Disord; 2018 Aug; 24():151-156. PubMed ID: 30015079 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]